Edaravone Combined with Clopidogrel Is Beneficial to Improve Efficacy, Neurological Impairment, and Life Function in Acute Cerebral Infarction Patients

Objective. This research aimed at investigating the efficacy of edaravone combined with clopidogrel on acute cerebral infarction (ACI) and its influence on the neurological deficit and life function. Methods. Totally, 154 ACI cases were included and then divided into the control group (CG) (n = 71) and research group (RG) (n = 83) according to the treatment methods. Patients in the CG were treated with clopidogrel alone, and those in the RG were under edaravone-clopidogrel combination therapy. The efficacy, adverse reactions, NIHSS score, cerebral hemodynamic indexes, and Fugl-Meyer scale (FMA) and Barthel index (BI) of activities of daily living (ADL) scores were observed. Results. Compared with before treatment, the symptoms of both groups were improved after treatment: the NIHSS scores decreased, FMA and ADL scores increased, and cerebral hemodynamic indexes were improved. Compared with the CG, the efficacy and cerebral hemodynamic indexes of the RG were better, the adverse reactions were equivalent, the NIHSS score was lower, and the ADL and FMA scores were higher. Conclusion. Edaravone combined with clopidogrel can effectively treat ACI and improve the neurological deficit and life function of patients.

Download Full-text

The Predictive Value of Serum Alkaline Phosphatase Level on the Degree of Neurological Impairment in Patients With Acute Cerebral Infarction

10.21203/rs.3.rs-1016602/v1 ◽

2021 ◽

Author(s):

Ji-ming Zou ◽

Xiao-yu Li ◽

Chao Han

Keyword(s):

Cerebral Infarction ◽

Serum Alkaline Phosphatase ◽

Pearson Correlation ◽

Multivariate Regression Analysis ◽

Neurological Impairment ◽

Serum Marker ◽

High Serum ◽

Acute Cerebral Infarction ◽

Control Group ◽

Nihss Score

Abstract ObjectiveTo analyze the correlation between the changes of ALP level and the degree of neurological impairment in patients with acute cerebral infarction. MethodsA total of 267 patients with acute cerebral infarction were selected as the cerebral infarction group, 181 elderly patients who were matched age and gender in the same period with the cerebral infarction group were selected as the control group by the physical examination. All the selected patients were tested for serum ALP, ALT, AST, Cr, BUN,TG, TC, LDL - C and HDL - C after eight hours on an empty stomach. In the 72nd hour of the patient's course of cerebral infarction, the degree of neurological impairment was assessed using NIHSS score. The relationship between serum ALP level and NIHSS score was analyzed. ResultsAccording to NIHSS score, the patients with score of 5~15 were Group A , patients with score of 15~20 were Group B and score of 21~42 were Group C. Pearson correlation analysis showed that the serum ALP level of the three groups was positively correlated with NIHSS score. Multivariate regression analysis results showed that the high serum ALP level of the risk of cerebral infarction is a low serum ALP level 1.58 times. ConclusionsSerum ALP level was increased in patients with acute cerebral infarction and was closely related to the degree of neurological impairment. Perhaps the serum ALP level may be used as a serum marker to predict the degree of neurological impairment in patients.

Download Full-text

Sequential butylphthalide therapy combined with dual antiplatelet therapy in the treatment of acute cerebral infarction

Pakistan Journal of Medical Sciences ◽

10.12669/pjms.36.4.1831 ◽

2020 ◽

Vol 36 (4) ◽

Author(s):

Xuewen Wo ◽

Jinyan Han ◽

Jiajia Wang ◽

Xinmin Wang ◽

Xiaoying Liu ◽

...

Keyword(s):

Plasma Level ◽

Cerebral Infarction ◽

Antiplatelet Therapy ◽

Adverse Reactions ◽

Dual Antiplatelet Therapy ◽

Acute Cerebral Infarction ◽

Control Group ◽

Observation Group ◽

Significant Difference ◽

Better Than

Objective: To observe the clinical efficacy of sequential butylphthalide therapy combined with dual antiplatelet therapy in the treatment of elderly patients with acute cerebral infarction (ACI). Methods: One hundred and twenty-two elderly patients with ACI who were admitted to the department of neurology of our hospital at May 2016-August 2018 were selected grouped into a control group and an observation group by random number table method, 61 in each group. On the basis of conventional treatment, the patients in the control group were given dual antiplatelet therapy (aspirin enteric-coated tablets + clopidogrel bisulfate tablets), while the patients in the observation group were given sequential butylphthalide therapy on the basis of the control group. The clinical effects of the two groups were compared after four weeks of treatment, and the changes of National Institutes of Health Stroke Scale (NIHSS), ADL score, plasma 3-mercaptopyruvate sulphurtransferase (3-MST) and Amyloid β42 (Aβ42) levels and the occurrence of adverse reactions during treatment were recorded. Results: The clinical efficacy of the observation group was better than that of the control group (P<0.05). There was no significant difference in NIHSS and ADL scores between the two groups before treatment (P>0.05). After treatment, the NIHSS and ADL scores of the observation group were better than those of the control group (P<0.05). There was no significant difference in plasma levels of 3-MST and AB42 between the two groups before treatment (P>0.05). The level of plasma 3-MST in the observation group was higher than that in the control group, and the level of plasma Aβ42 was lower than that in the control group (P<0.05). No serious adverse reactions occurred during the treatment period in both groups. Conclusion: Butylphthalide sequential therapy combined with dual antiplatelet therapy is effective in the treatment of elderly ACI. It can effectively improve the plasma level of 3-MST and decrease the plasma level of Aβ42, which is conducive to improving the living ability and neurological function of patients and has high safety. doi: https://doi.org/10.12669/pjms.36.4.1831 How to cite this:Wo X, Han J, Wang J, Wang X, Liu X, Wang Z. Sequential butylphthalide therapy combined with dual antiplatelet therapy in the treatment of acute cerebral infarction. Pak J Med Sci. 2020;36(4):---------. doi: https://doi.org/10.12669/pjms.36.4.1831 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Download Full-text

Intravenous thrombolysis in combination with mild hypothermia therapy in the treatment of acute cerebral infarction

Pakistan Journal of Medical Sciences ◽

10.12669/pjms.35.4.311 ◽

2019 ◽

Vol 35 (4) ◽

Cited By ~ 3

Author(s):

Xiaoying Liu ◽

Shengli Rao ◽

Jiajia Wang

Keyword(s):

Cerebral Infarction ◽

Conventional Treatment ◽

Mild Hypothermia ◽

Intravenous Thrombolysis ◽

Acute Cerebral Infarction ◽

Control Group ◽

Observation Group ◽

Nihss Score ◽

Time Points ◽

Before And After

Objective: To investigate the efficacy of recombinant tissue plasminogen activator (rt-PA) intravenous thrombolysis in combination with mild hypothermia therapy in the treatment of acute cerebral infarction. Methods: One hundred and thirty-two patients with acute cerebral infarction who were admitted to our hospital were selected and grouped into a control group and an observation group, 66 each group. Patients in the control group were given conventional treatment in combination with local mild hypothermia therapy, and patients in the observation group were given rt-PA intravenous thrombolysis on the basis of conventional treatment and local mild hypothermia therapy. National institute of health stroke scale (NIHSS) score and intracranial pressure (ICP) of the two groups before and after treatment was recorded. The efficacy of the two groups was evaluated. The modified Rankin scale (MRS) score was followed up for three months. The blood samples of the patients were collected before and after thrombolysis. Superoxide dismutase (SOD) and malondialdehyde (MDA) levels in the plasma were detected. Results: The NIHSS score of the two groups decreased in the 1st, 3rd and 7th day after treatment compared to before treatment (p<0.05), but the NIHSS score of the two groups had no significant difference at different time points after treatment (p>0.05). The ICP of the two groups decreased in the 1st, 3rd and 7th day after treatment compared to before treatment (p<0.05), and the decrease of ICP of the observation group was more significant than that of the control group at the same time point (1st, 3rd and 7th day after treatment) (p<0.05). The clinical efficacy of the observation group was higher than that of the control group after treatment, and the difference was statistically significant (p<0.05). The MDA concentration of both groups decreased at different time points after treatment (p<0.05), but the SOD concentration increased (p<0.05). The MDA concentration of the observation group was lower than that of the control group at different time points after treatment (p<0.05), and the SOD concentration of the observation group was higher than that of the control group (p<0.05). Conclusion: rt-PA intravenous thrombolysis in combination with mild hypothermia therapy has significant efficacy in the treatment of acute cerebral infarction. It can effectively relieve neurological function. Its action mechanism may be realized by relieving oxidative stress response. doi: https://doi.org/10.12669/pjms.35.4.311 How to cite this:Liu X, Rao S, Wang J. Intravenous thrombolysis in combination with mild hypothermia therapy in the treatment of acute cerebral infarction. Pak J Med Sci. 2019;35(4):1161-1166. doi: https://doi.org/10.12669/pjms.35.4.311 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Download Full-text

Clinical Study on Treatment of Patients with Acute Cerebral Infarction by Huayu Tongluo Decoction Combined with Edaravone Injection

E3S Web of Conferences ◽

10.1051/e3sconf/202018503011 ◽

2020 ◽

Vol 185 ◽

pp. 03011

Author(s):

Wentao Zhang ◽

Ping Zuo ◽

Feng Wang ◽

Zhihua Liu ◽

Yinglin Cui

Keyword(s):

Quality Of Life ◽

Cerebral Infarction ◽

Clinical Effect ◽

Clinical Symptoms ◽

Effective Rate ◽

Acute Cerebral Infarction ◽

Control Group ◽

Study Group ◽

Nihss Score

To study the clinical effect of Huayu Tongluo Decoction combined with edaravone injection in the treatment of patients with acute cerebral infarction.86 patients with acute cerebral infarction received from our hospital from October 2016 to May 2018 were randomly divided into study group (n=43) and control group (n=43). Routine treatment was performed in both groups. On the basis of this, the control group was treated with edaravone injection, and the research group was treated with Huayu Tongluo Decoction combined with edaravone injection. The effects of treatment, the degree of neurological deficit (NIHSS score), TCM syndrome scores and quality of life (QLI score) before and after treatment were compared. The total effective rate of the study group [95.35% (41/43)] was higher than that of the control group [79.07% (34/43)] (P<0.05). After treatment, the main symptoms, secondary diseases and tongue and pulse of the two groups were treated. The scores were lower than before treatment, and the study group was lower than the control group (P<0.05). After treatment, the NIHSS and QLI scores of the two groups were better than before treatment, and the NIHSS score of the study group was lower than that of the control group, and the QLI score was higher than the control. Group (P<0.05). The clinical effect of Huayu Tongluo Decoction combined with edaravone injection in the treatment of patients with acute cerebral infarction is significant, which can further improve the clinical symptoms, improve neurological function and improve the quality of life.

Download Full-text

Butyphthalide in the treatment of massive Cerebral Infarction

Pakistan Journal of Medical Sciences ◽

10.12669/pjms.35.1.320 ◽

2019 ◽

Vol 35 (1) ◽

Author(s):

Xinmin Wang ◽

Yingjun Sun ◽

Shugang Dong ◽

Xiaoying Liu ◽

Jinming Ji

Keyword(s):

Treatment Group ◽

Cerebral Infarction ◽

Daily Living ◽

Statistical Significance ◽

Response Rates ◽

Control Group ◽

Activity Of Daily Living ◽

Nihss Score ◽

Before And After ◽

The Difference

Objective: To evaluate the effect of butyphthalide in the treatment of massive cerebral infarction. Methods: One hundred and twenty patients with massive cerebral infarction who were admitted to the hospital between January 2017 and December 2017 were selected and divided into a treatment group (n = 60) and a control group (n = 60) using random number table, 80 each group. Patients in the control group were given conventional cerebral infarction therapy, while patients in the treatment group were given butyphthalide injection besides the conventional treatment. The National Institutes of Health Stroke Scale (NIHSS) score, score of activity of daily living (ADL), lipoprotein-associated phospholipase A2 (LP-PLA2) and prognosis were recorded and compared between the two groups. The response rates of the two groups were recorded. Results: The total response rates of the control group and treatment group were 73.85% and 93.85% respectively at the postoperative 21st day, and the difference had statistical significance (P<0.05). The NIHSS score of the two groups obviously decreased, and the ADL score significantly increased after treatment; the differences of NIHSS score and ADL score before and after treatment in the same group had statistical significance (P<0.05). The improvement of the indexes of the treatment group was obviously superior to that of the control group, and the differences between the two groups had statistical significance (P<0.05). The level of LP-PLA2 of both groups significantly decreased at the postoperative 21st day, and the difference before and after treatment in the same group was statistically significant (P<0.05); the treatment group had a significantly lower level of LP-PLA2 than the control group, and the difference had statistical significance (P<0.05). The treatment group had significantly higher positive outcome rate and lower mortality rate than the control group at the postoperative 90th day, and the differences had statistical significance (P<0.05). The incidence of adverse events of the treatment group and control group was 8.3% (5/60) and 5.0% (3/60) respectively, suggesting no significant difference (P>0.05). Conclusion: Butyphthalide has a favourable effect in treating massive cerebral infarction. It can repair neurologic impairment, improve activity of daily living, and adjust the level of LP-PLA2, suggesting favourable application values. How to cite this:Wang X, Sun Y, Dong S, Liu X, Ji J. Butyphthalide in the treatment of massive Cerebral Infarction. Pak J Med Sci. 2019;35(1):---------. doi: https://doi.org/10.12669/pjms.35.1.320 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Download Full-text

Donepezil Improves Gait Performance in Patients with an Acute Cerebral Infarction: A Prospective Observational Cohort Study

Current Neurovascular Research ◽

10.2174/1567202617666200413130101 ◽

2020 ◽

Vol 17 (3) ◽

pp. 304-311 ◽

Cited By ~ 1

Author(s):

Ying-Ying Lin ◽

Shi-Jie Guo ◽

Hui Quan ◽

Yan-Xin Zhao ◽

Dong-Ya Huang

Keyword(s):

Risk Factors ◽

Cerebral Infarction ◽

Acute Cerebral Infarction ◽

Control Group ◽

Observation Group ◽

Gait Performance ◽

Nihss Score ◽

Significant Difference ◽

Independent Risk Factors ◽

And Control

Background: Hemiplegia is a common symptom after acute cerebral infarction. Objective: This study aimed to explore the influence factors of gait performance and investigate whether donepezil could improve gait performance in patients with an acute cerebral infarction. Methods: A total of 107 patients who experienced unilateral paresis after an acute cerebral infarction incident were enrolled in this prospectively observational study. Participants underwent a 3- month assessment. At the study's conclusion, patients were divided into 2 groups-those who received donepezil daily (observation Group) and those who did not (Control Group). Results: There was a significant difference (t=3.269, P=0.001) of Wisconsin Gait Scale (WGS) score between single site infarction (27.11±6.65) and multiple sites infarction (31.54±6.42). For gender, smoking, drinking, hypertension, hyperlipidemia and diabetes, there was no difference in WGS scores between subgroups (P>0.05), respectively. The patient's admission National Institute of Health Stroke Scale(NIHSS) score had a strongly positive correlation with WGS score (r=0.850, P<0.001). Besides, age (r=0.218, P=0.024), glycosylated hemoglobin (r=0.274, P=0.004), MMSE (r=-0.261, P=0.007) and Montreal Cognitive Assessment (MoCA) (r=-0.272, P=0.005) had a weak correlation with WGS scores. Multivariate analysis showed age (95% CI: 0.042~0.188, P=0.002), admission NIHSS score (95% CI: 2.405~3.137, P<0.001) and multiple sites infarction (95% CI: 0.044~2.983, P=0.044) were independent risk factors of WGS scores. WGS scores of both observation and control groups gradually decreased after admission (P<0.001). At 3 months after admission, WGS score of the observation group was significantly lower than the control group (t=2.468, P=0.015). There were no significant differences between observation and control group at admission and 1 month after admission (P>0.05) and WGS scores of both single site and multiple sites infarction gradually decreased at one month and three months after admission (P<0.001), while there was no significant difference between two groups (P>0.05). Conclusion: Admission NIHSS score, age and multiple sites infarction were independent risk factors of WGS score. Donepezil could improve gait performance in patients with acute cerebral infarction.

Download Full-text

Clinical Study of Urinary Kallidinogenase in the Treatment of Progressive Cerebral Infarction

Advanced Emergency Medicine ◽

10.18686/aem.v2i1.5 ◽

2013 ◽

Vol 2 ◽

pp. 13

Author(s):

Binghui Fan ◽

Weidong Li

Keyword(s):

Treatment Group ◽

Cerebral Infarction ◽

Adverse Reactions ◽

Total Effective Rate ◽

Neurological Impairment ◽

Effective Rate ◽

Control Group ◽

Before And After ◽

And Control ◽

Better Than

Objective: To evaluate the efficacy and safety of Urinary kallidinogenase in the treatment of progressive cerebral infarction. Method: 104 cases of patients with acute cerebral infarction were randomly divided into treatment group and control group; where control group (52 cases) patients on with only basic medicine, while treatment group (52 cases), besides the basic medicine, patients will on urinary kallidinogenase 0.15 PNAU + 0.9% normal saline 100 mL intravenous injection, 1 times per day, and continuous for 14 days. The degree of neurological impairment (NIHSS) was assessed before and after treatment, and the changes of blood pressure were monitored. The liver, renal function, fibrinogen, platelet, and the adverse reactions were recorded and followed up in three month. Results: After treatment, NIHSS scores of the both groups were decreased (p < 0.05), however, total effective rate for treatment group were better than control group (p < 0.05). Conclusion: Urinary kallidinogenase is safe and effective in the treatment of progressive cerebral infarction.

Download Full-text

Effect of Argatroban Injection on Clinical Efficacy in Patients with Acute Cerebral Infarction: Preliminary Findings

European Neurology ◽

10.1159/000512813 ◽

2021 ◽

pp. 1-5

Author(s):

Pan Huang ◽

Xiao-ying He ◽

Min Xu

Keyword(s):

Treatment Group ◽

Cerebral Infarction ◽

Clinical Efficacy ◽

Adverse Reactions ◽

National Institutes Of Health ◽

Acute Cerebral Infarction ◽

Control Group ◽

Scale Scores ◽

The Difference ◽

And Control

Objective: The aim is to observe the effects of argatroban injection and butylphthalide injection on blood flow rheology, clinical efficacy, and safety in patients with acute cerebral infarction. Methods: 344 patients with acute cerebral infarction within 48 h after admission were divided into treatment group and control group, with 172 cases in each group. The control group received routine treatment. The treatment group received argatroban injection 60 mg on the basis of the control group, intravenously guttae (ivgtt) was used for 2 days and then changed to argatroban injection 10 mg, ivgtt bid for 5 days, and the total course of treatment was 7 days. The neurological changes, activities of daily living, and the rheology indicators (fibrinogen [Fib], platelet aggregation rate [Pag], whole blood high shear viscosity [Whsv], hematocrit [Hct]) were compared between the 2 groups, clinical efficacy and adverse drug reactions. Results: After treatment, the total effective rates of the treatment group and the control group were 90.70% (156 /172 cases) and 74.41% (128 and 172 cases), respectively, and the difference was statistically significant (p < 0.05). After treatment, the National Institutes of Health Stroke Scale scores of the treatment group and the control group were (7.05 ± 1.97) and (8.30 ± 1.79), respectively, and the Barthel index was (68.02 ± 11.07) and (62.32 ± 11.46), respectively. The difference was statistically significant (p < 0.05). After treatment, the treatment group and the control group were (2.66 ± 0.22) g/L and (3.50 ± 0.22) g/L, respectively, and Pag were (0.68 ± 0.06)% and (0.81 ± 0.09)%, respectively, and Whsv was (6.44 ± 0.76) mPs/s and (6.87 ± 0.91) mPs/s, Hct were (8.19 ± 1.21)% and (10.44 ± 1.04)%, respectively, and the differences were statistically significant (p < 0.05). The incidence of adverse reactions in the treatment group and the control group was 6.97 and 5.81%, respectively, and the difference was not statistically significant (p > 0.05). Conclusion: Argatroban injection is effective in the treatment of acute cerebral infarction, which can significantly improve the hemorheology of patients with good safety.

Download Full-text

Clinical Efficacy of Neurointerventional Catheter Thrombolysis for Cerebral Infarction

Journal of Clinical and Nursing Research ◽

10.26689/jcnr.v3i6.867 ◽

2019 ◽

Vol 3 (6) ◽

Author(s):

Qiangyuan Tian ◽

Guangchao Zhu ◽

Shugang Dong

Keyword(s):

Cerebral Infarction ◽

Clinical Efficacy ◽

Neurological Deficit ◽

Arterial Catheter ◽

Control Group ◽

Observation Group ◽

Nihss Score ◽

Before And After ◽

Catheter Thrombolysis ◽

Better Than

Objective: To analyze the clinical efficacy of neurointerventional catheter thrombolysis for cerebral infarction. METHODS: A total of 56 patients with cerebral infarction admitted to our hospital from April 2018 to June 2019 were enrolled for the experimental study. Two different treatments were applied to patients, and patients were divided into observation groups and controls according to different treatment methods. After grouped into two groups the control group was treated with intravenous thrombolysis. The observation group was treated with neurointerventional arterial catheter thrombolysis. The treatment effect, NIHSS score and BI index, neurological deficit score before and after treatment, and coagulation index were compared between the two groups. RESULTS: The therapeutic effect of the observation group (92.86%) was significantly different from that of the control group (67.86%), and the observation group was higher than the control group. The data of the observation group in the NIHSS score and the BI index were 5.42±1.77 and 95.64±2.15, respectively, which were better than the control group. The neurological deficit scores of the observation group before and after treatment were 19.88±6.24 and 9.14±5.81, respectively. After treatment, the difference was significant compared with the control group, p<0.05. The coagulation indexes of the observation group in FIB, PT, TT, etc. were respectively 3.68±1.04, 11.46±1.62, 15.37±2.46, all were better than the control group (2.13±0.47, 13.72±2.72, 19.85±2.62), P<0.05. Conclusion: the clinical efficacy of neurointerventional arterial catheter thrombolysis for cerebral infarction is significant, it can effectively promote the recovery of various functional conditions of patients with cerebral infarction, which is worthy of further application and promotion.

Download Full-text

Effect of Comprehensive Cerebral Protection Program on Cerebral Oxygen Metabolism and Vascular Endothelial Function in Elderly Patients with Acute Cerebral Infarction

Iranian Journal of Public Health ◽

10.18502/ijph.v48i2.828 ◽

2019 ◽

Author(s):

Meihong ZHOU ◽

Zhaojun HUANG

Keyword(s):

Elderly Patients ◽

Cerebral Infarction ◽

Endothelial Function ◽

Oxygen Metabolism ◽

Acute Cerebral Infarction ◽

Control Group ◽

Cerebral Oxygen ◽

Vascular Endothelial ◽

Vascular Endothelial Function ◽

Cerebral Oxygen Metabolism

Background: We aimed to explore the effect of comprehensive cerebral protection on cerebral oxygen metabolism and vascular endothelial function in elderly patients with acute cerebral infarction. Methods: A total of 168 elderly patients with acute cerebral infarction treated in The First Affiliated Hospital of Nanchang University, China from January 2016 to January 2018 were selected. The patients were divided into a control group and an observation group using random number method, n=84. Patients in the observation group were given comprehensive cerebral protection treatment, and patients in the control group were treated with conventional standardized treatments. The changes of cerebral oxygen metabolism, hemorheology and vascular endothelial function before and after treatment were compared between the two groups. Results: After treatment, oxygen content in arteries and internal jugular veins (Da-vO2), ofoxygen uptake fraction (OEF), Oxygen saturation (SpO2), nitric oxide (NO) were increased in both groups in comparison to before treatment, jugular venous oxygen saturation (SjvO2), brain oxygen uptake rate (ERO2), endothelin (ET), intracranial pressure (ICP), whole blood viscosity, plasma viscosity, reduced viscosity of whole blood, and hematocrit were decreased. However, the changes in the observation group were larger than those in the control group, the difference was statistically significant (P<0.05). Conclusion: The treatment of cerebral infarction in elderly patients with acute cerebral infarction can effectively improve the cerebral oxygen metabolism and vascular endothelial function and improve the blood rheology, which has important clinical value.

Download Full-text